Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs — Oct 9th, 2024

Research and Development Expenses: $39.7 million for Q2 2024, up from $28.2 million in Q2 2023. General and Administrative Expenses: $16.7 million for Q2 2024, compared to $11.8 million in Q2 2023. Net Loss: $50.8 million for Q2 2024, compared to $37.2 million in Q2 2023. Noncash Share-Bas...

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology — Sep 30th, 2024

Kura Oncology, Inc. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 ...